Dossier assessment
Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Report documents
-
Extract of dossier assessment
Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
-
Dossier assessment
Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Dossier assessment
Pretreated and treatment-naive patients with at least 4 migraine days per month who are candidates for conventional migraine prophylaxis (subpopulation of the approved therapeutic indication)
Indication of a non-quantifiable added benefit (at least “considerable”).
Project details
- Project no.
- A21-58
- Commission
- Commission awarded on 03.05.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed